Since the beginning of the COVID-19 pandemic, the Division of Infectious Diseases (ID) has conducted cutting-edge research on SARS-CoV-2/COVID-19 pathogenesis, epidemiology/clinical course/outcomes, therapeutics, and prevention, including vaccine development.
Highlights and ongoing divisional work include:
Butt, Calfee, Craney, Drelick, Ellman, Ellsworth, Glesby, Gulick, Henry, Johnston, Kodiyanplakkal, Marks, Mazur, Miller, Plate, Satlin, Salvatore, Singh, Small, Soave, Vogler, Walsh, Westblade, Wilkin
The Division of General Internal Medicine created a COVID-19 registry with detailed clinical data suitable for epidemiological investigation. Examples of collaborations using this database include:
Drs. Calfee, Singh and Westblade contributed to New York City Department of Health sentinel surveillance efforts for COVID-19 cases and genetic analyses of viral isolates (published in MMWR).
Drs. Ellsworth and Gulick collaborated with the Department of Pathology on an assessment of red blood cell transfusion needs in patients with COVID-19 (manuscript submitted).
Dr. Gulick co-authored a review article on severe COVID-19 with colleagues in the Division of Pulmonary & Critical Care (published in New England Journal of Medicine).
Dr. Miller and Henry described the clinical experience with COVID-19 at the Hospital for Special Surgery, a specialty orthopedic hospital that was converted to a pandemic overflow field hospital (published in HSS J).
Brown, Copertino, Corley, Craney, de Mulder Rougvie, Duarte, Ellsworth, Gulick, Iñiguez, Jones, Kapadia, Marin-Hernandez, Morales, Ndhlovu, Nixon, Petraitis, Powell, Saito, Salvatore, Satlin, Singh, Soave, Vorkas, Westblade, Walsh, Wilkin
Drs. Corley and Ndhlovu collaborated with colleagues from OHSU describe virological and immunological consequences of disruption of the CCL5/RANTES-CCR5 pathway in critical COVID-19 (pre-print published).
Mr. Copertino and Drs. de Mulder Rougvie, Duarte, Gulick, Nixon and Wilkin reported on antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection (pre-print published).
Drs. Craney, Salvatore, ad Westblade collaborated with colleagues from the Department of Physiology on the characterization of COVID-19 isolates in NYC and the development of a novel diagnostic method (pre-print published).
Drs. Craney, Satlin, and Westblade in collaboration with additional colleagues from the Department of Pathology compared two high-throughput reverse transcription-PCR systems for SARS-CoV-2 (published in the Journal of Clinical Microbiology).
Drs. Duarte, Iñiguez, Nixon, and Powell, Mr. Copertino and WCM medical student Jez Marston reported a data-driven approach to repurposing FDA-approved drugs for COVID-19 (pre-print published).
Drs. Ellsworth and Wilkin worked with colleagues in Department of Pathology and the blood bank to determine clinical factors in COVID-19 that were predictive of serologic responses in a convalescent plasma donor screening program (manuscript in preparation).
Dr. Jones co-authored a study that reported suboptimal biological sampling as a probable cause of false-negative COVID-19 diagnostic test results (published in the Journal of Infectious Diseases).
Dr. Jones co-authored a study that reported SARS-CoV-2-specific T-cells can be rapidly expanded for therapeutic use and target conserved regions of the membrane protein, (manuscript under revision in Blood).
Dr. Jones made his BSL-2+ space available as the primary site of processing of blood samples from SARS-CoV2-infected donors, for the WCMC Biobank effort (with Dr. Ross). He also supplied protocols to several other laboratories to establish their BSL-2+ procedures.
Drs. Marín-Hernández and Nixon and colleagues from the Division of Gastroenterology published epidemiological evidence for an association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy (published in the Journal of Medical Virology).
Dr. Ndhlovu collaborated with colleagues from the Division of Cardiology on the additive prognostic utility of adverse right ventricular remodeling in relation to conventional risk stratification among patients with COVID-19 (manuscript in press, Journal of the American College of Cardiology).
Drs. Ndhlovu and Corley worked with colleagues from Mount Sinai and report on the overlap of intestinal inflammation and the pathogenesis of COVID-19 related disease on the SAR-CoV-2 receptors (manuscript in press, Gastroenterology).
Dr. Nixon with medical students Jez Marston and Robert Wozniak reported on involvement of cisgender and transgender individuals in studies on the impact of hormonal therapy on COVID-19 (published in AIDS Patient Care and STDs).
Drs. Petraitis and Walsh used focal multivector ultraviolet technology (FMUV) for environmental control of SARS CoV-2 (technical report published).
Dr. Salvatore with colleagues Drs. Brown, Ellsworth, Kapadia, Morales, Saito, Singh, Soave, and Vorkas, working with a broad multi-disciplinary group recruited subjects to develop a biobank of specimens from hospitalized patients with acute COVID-19 as well as from outpatients who recovered (convalescent) to determine virologic and immunologic determinants of disease recovery or progression (pre-print published).
Drs. Satlin and Westblade collaborated on a retrospective cohort study of blood culture utilization in COVID-19 and found bacteremia was very rare (published in the Journal of Clinical Microbiology).
Dr. Walsh in collaboration with Dr. Matt McCarthy received a grant from the Henry Schueler Foundation for translational research for new therapeutics with binary antiviral and anti-inflammatory properties in treatment of COVID-19.
Butt, Drelick, Ellsworth, Glesby, Gulick, Horowitz, Kapadia, Marks, Singh, Small, Walsh, Wilkin
Drs. Horowitz, Kapadia, Marks, Miller and Singh conducted the expanded access/compassionate use study of remdesivir.
Dr. Marks conducted a Phase 3 randomized study of remdesivir in severe COVID-19 (published in the New England Journal of Medicine).
Dr. Marks also conducted a phase 3 randomized study to evaluate safety and antiviral activity of remdesivir in moderate COVID-19 (published in JAMA).
Drs. Small and Walsh co-led a phase 2 study of selinexor for severe COVID-19 (manuscript in preparation):
Dr. Glesby conducted an adaptive Phase 2/3 study of the safety and efficacy of sarilumab, an IL6 antagonist, for severe COVID-19 (manuscript in preparation).
Dr. Butt is a member of the Scientific Review and Reference Team and the Policy, Planning and Performance Team of the Ministry of Public Health in Qatar.
Dr. Gulick co-chairs the U.S. NIH COVID 19 Treatment Guidelines Panel.
Dr. Butt is a member of the Hamad Medical Center, Qatar Ad Hoc COVID-19 Research Prioritization Committee.
Dr. Pape coordinated COVID-19 efforts in Haiti.
Weill Cornell COVID-19 Clinical Research Task Force: Dr. Gulick, chair; Drs. Glesby, Marks, Walsh, members.